Gavin Bart, MD, PhD

Division of Addiction Medicine, Hennepin Healthcare, Minneapolis, Minnesota

JCP
Early Change in Depressive Symptom Severity with Naltrexone-Bupropion Combination and Its Association with Reduction in Methamphetamine Use: ADAPT-2 Trial
Original Research

July 30, 2025

Improvement in depression accounted for approximately 25% of the treatment effect of naltrexone-bupropion on methamphetamine treatment response.
, , , et al

Expert Consensus on Aripiprazole LAIs in Clinical Practice

Read the full report
Figure shows a syringe and vials with title on aripiprazole monohydrate LAI use in schizophrenia and a red READ NOW button.

Subscribe to read
more articles

Subscribe